Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada-Reference-Cited by-同舟云学术

Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada

Published:2014-08 Issue:1 Volume:51 Page:25-34
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Huisman Eline L.,van Eerd Margreet C.,Ouwens J.N. Mario,de Peuter Maria A.

Funder

Octapharma AG

Publisher

Elsevier BV

Subject

Hematology

Reference42 articles.

1. Update on pathogen reduction technology for therapeutic plasma: an overview;Solheim;Transfus Apher Sci,2006

2. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma;Riedler;Vox Sang,2003

3. Modeling the risk of an emerging pathogen entering the Canadian blood supply;Kleinman;Transfusion,2010

4. Pathogen reduction of blood components;Solheim;Transfus Apher Sci,2008

5. Introduction of Octaplas in clinical use decreased the rate of severe adverse reactions;Krusius;Vox Sang,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thirty years of experience with solvent/detergent‐treated plasma for transfusion medicine;Transfusion;2024-04-21

2. Pharmacologic Hemostatic Agents in Total Joint Arthroplasty—A Cost-Effectiveness Analysis;The Journal of Arthroplasty;2018-07

3. Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage;Anesthesiology;2018-02-01

4. Past, present and forecast of transfusion medicine: What has changed and what is expected to change?;La Presse Médicale;2016-07

5. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital;Vox Sanguinis;2016-02-25